Table 2.
Quality of different antimalarials, antiretrovirals and antituberculosis medicines obtained from health facilities and storage areas across the 10 provinces of Zambia between January 2018 and June 2023.
| API (international non-proprietary name) | n | Quality test result |
||
|---|---|---|---|---|
| Pass | Fail | Overall pass, n (%) | ||
| Antimalarials | ||||
| Artemether/Lumefantrine | 50 | 50 | 0 | 50 (100) |
| Sulphadoxine/Pyrimethamine | 2 | 2 | 0 | 2 (100) |
| Artesunate | 2 | 2 | 0 | 2 (100) |
| Antiretrovirals | ||||
| Tenofovir/Lamivudine/Efavirenz | 11 | 11 | 0 | 11 (100) |
| Tenofovir/Lamivudine | 8 | 8 | 0 | 8 (100) |
| Efavirenz | 9 | 9 | 0 | 9 (100) |
| Lamivudine | 4 | 4 | 0 | 4 (100) |
| Lopinavir/Ritonavir | 7 | 7 | 0 | 7 (100) |
| Atazanavir/Ritonavir | 5 | 5 | 0 | 5 (100) |
| Abacavir/Lamivudine | 3 | 3 | 0 | 3 (100) |
| Dolutegravir/Lamivudine/Tenofovir | 15 | 15 | 0 | 15 (100) |
| Dolutegravir | 3 | 3 | 0 | 3 (100) |
| Tenofovir/Emtricitabine | 10 | 10 | 0 | 10 (100) |
| Abacavir | 3 | 3 | 0 | 3 (100) |
| Dolutegravir/Emtricitabine/Tenofovir | 1 | 1 | 0 | 1 (100) |
| Nevirapine | 1 | 1 | 0 | 1 (100) |
| Lamivudine/Zidovudine | 6 | 6 | 0 | 6 (100) |
| Antituberculosis drugs | ||||
| Rifampicin/Isoniazid/Pyrazinamide/Ethambutol | 12 | 12 | 0 | 12 (100) |
| Rifampicin/Isoniazid/Pyrazinamide | 6 | 6 | 0 | 6 (100) |
| Rifampicin/Isoniazid/Ethambutol | 2 | 2 | 0 | 2 (100) |
| Rifampicin/Isoniazid | 8 | 8 | 0 | 8 (100) |
| Isoniazid | 24 | 24 | 0 | 24 (100) |
| Ethambutol | 5 | 5 | 0 | 5 (100) |
| Cycloserine | 1 | 1 | 0 | 1 (100) |